학술논문
CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study
Document Type
Article
Author
Munir, Talha ; Moreno, Carol ; Owen, Carolyn ; Follows, George ; Benjamini, Ohad ; Janssens, Ann ; Levin, Mark-David ; Osterborg, Anders ; Robak, Tadeusz ; Simkovic, Martin ; Stevens, Don ; Voloshin, Sergey ; Vorobyev, Vladimir ; Yagci, Munci ; Ysebaert, Loic ; Qi, Qianya ; Steele, Andrew ; Schuier, Natasha ; Baeten, Kurt ; Caces, Donne Bennett ; Niemann, Carsten ; Kater, Arnon
Source
In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S264-S265
Subject
Language
ISSN
2152-2650